Top Markets
#1 Islamic Coin Islamic Coin +158.18%
#2 Glidr Glidr +58.56%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.45%
#4 Victoria VR Victoria VR +15.43%
#5 Cryptopia Cryptopia +15.32%
#6 Palladium Network Palladium Network +9.40%
#7 Movement Movement +7.88%
#8 龙虾 (Lobster) 龙虾 (Lobster) +7.67%
#9 Pons Pons +7.17%
#10 COTI COTI +7.08%
Coin of the day
Islamic Coin Islamic Coin
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.

Samsung Biologics Co.,Ltd.

207940
Rang in Aktien #518
Samsung Biologics Co.,Ltd., established in 2011 and headquartered in Incheon,... Samsung Biologics Co.,Ltd., established in 2011 and headquartered in Incheon, South Korea, provides contract services for biopharmaceutical products. The company's operations are divided into two main segments: Contract Manufacturing Organization (CMO) and Contract Development Organization (CDO). Its CDO services cover areas such as cell line development, optimization of upstream and downstream processes, and the formulation of analytical methods and final products. For CMO, the company offers aseptic filling, lyophilization, finishing, storage, shipping, and various associated support services. Additionally, it delivers comprehensive quality assurance, quality control, biosafety, and analytical testing. Samsung Biologics is also involved in creating and launching biosimilar drugs, alongside manufacturing mammalian cell-based antibody medications.
Aktienkurs
$1,075.96
Marktkapitalisierung
$49.81B
Veränderung (1 Tag)
0.45%
Veränderung (1 Jahr)
-7.16%
Land
KR
Handel Samsung Biologics Co.,Ltd. (207940)

Kategorie

Healthcare
P/S-Verhältnis für Samsung Biologics Co.,Ltd. (207940)
P/S-Verhältnis zum 2026 TTM: 0
Laut den neuesten Finanzberichten und dem Aktienkurs von Samsung Biologics Co.,Ltd. beträgt das aktuelle Kurs-Umsatz-Verhältnis (TTM) 0. Am Ende des Jahres 2026 lag das P/S-Verhältnis bei 0.
P/S-Verlauf für Samsung Biologics Co.,Ltd. von 2026 bis 2026
P/S-Verhältnis zum Jahresende
Jahr P/S-Verhältnis ändert
Nicht genügend Daten für die angegebenen Daten.
P/S-Verhältnis für ähnliche Unternehmen oder Wettbewerber
Unternehmen P/S-Verhältnis P/S-Verhältnis-Differenz Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
9.88 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.30 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
4.98 -
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
2.64 -
AU